The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2022 | Clinical and genomic diagnosis of smoldering myeloma & identifying patients at risk of progression
Niccolò Bolli, MD, PhD, University of Milan, Milan, Italy, comments on the discordance between clinically and genomically-defined smoldering myeloma, explaining how this can be used to find patients at high risk of progression to multiple myeloma and initiate treatment early. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
